Transactions
6
Insider / Fulcrum Therapeutics, Inc.
TANG KEVIN
Insider at Fulcrum Therapeutics, Inc.
- Company
- Fulcrum Therapeutics, Inc.
- Ticker
- FULC
- First filing on record
- July 15, 2026
- Latest trade on record
- July 17, 2026
- SEC filings
- EDGAR ↗
TANG KEVIN, Insider at Fulcrum Therapeutics, Inc., has disclosed 6 transactions in FULC since July 15, 2026: 6 purchases (6 open-market buys) and 0 sales, worth about $1.5M at the reported prices. The latest was filed July 20, 2026, 3 days after the trade.
Open-market buys
6
Sales
0
Avg. disclosure lag
1.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months TANG KEVIN made 6 purchases worth $1.5M and no sales. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
TANG KEVIN has traded 1 stock on record; the largest by dollars is FULC.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| P | Open-market purchase | 6 | 417,562 | $1.5M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 6 | 6 · $1.5M | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| FULC | Buy P | July 17, 2026 | July 20, 2026 | 3d | 50,945 | $4 | $179K | indirect | Form 4 ↗ | |
| FULC | Buy P | July 16, 2026 | July 20, 2026 | 4d | 116,671 | $4 | $415K | indirect | Form 4 ↗ | |
| FULC | Buy P | July 15, 2026 | July 15, 2026 | 0d | 107,377 | $4 | $382K | indirect | Form 4 ↗ | |
| FULC | Buy P | July 14, 2026 | July 15, 2026 | 1d | 75,952 | $4 | $272K | indirect | Form 4 ↗ | |
| FULC | Buy P | July 14, 2026 | July 15, 2026 | 1d | 53,651 | $4 | $191K | indirect | Form 4 ↗ | |
| FULC | Buy P | July 13, 2026 | July 15, 2026 | 2d | 12,966 | $4 | $46K | indirect | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 20, 2026 | Form 4 | 0001178579-26-000016 | 2 | published | EDGAR ↗ |
| July 15, 2026 | Form 4 | 0001178579-26-000014 | 4 | published | EDGAR ↗ |
Other insiders at Fulcrum Therapeutics, Inc.
- Sanofi Insider 24 rows
- Ezekowitz Alan Director 2 rows
- Banks Sonja Director 1 row
- Dorton Katina Director 1 row
- GERAGHTY JAMES A Director 1 row
- Gould Robert J Director 1 row
- Haviland Kate Director 1 row
- Hill Colin Director 1 row
- King Rachel K. Director 1 row
Everyone on file, with contracts and lobbying under the company's name: Fulcrum Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 6 | July 15, 2026 | July 20, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.